vadimezan has been researched along with ekb 569 in 1 studies
| Studies (vadimezan) | Trials (vadimezan) | Recent Studies (post-2010) (vadimezan) | Studies (ekb 569) | Trials (ekb 569) | Recent Studies (post-2010) (ekb 569) |
|---|---|---|---|---|---|
| 272 | 16 | 101 | 68 | 5 | 33 |
| Protein | Taxonomy | vadimezan (IC50) | ekb 569 (IC50) |
|---|---|---|---|
| Epidermal growth factor receptor | Homo sapiens (human) | 0.0489 | |
| Receptor tyrosine-protein kinase erbB-2 | Homo sapiens (human) | 1.2298 | |
| Vascular endothelial growth factor receptor 2 | Homo sapiens (human) | 3.131 | |
| Serine/threonine-protein kinase Nek2 | Homo sapiens (human) | 0.661 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
1 other study(ies) available for vadimezan and ekb 569
| Article | Year |
|---|---|
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |